Literature DB >> 26912901

Eco-evolution of cancer resistance.

Giannoula L Klement1.   

Abstract

For the past 60 years, the goal of conventional cancer therapies has been the eradication of every cancer cell. To this end, patients are subjected to the highest possible doses of radiation and chemotherapy as well as radical surgeries. In the rare case in which eradication was possible, clinicians achieved long-term control of the disease. For the most part, however, upfront eradication is not possible, and despite intensive and very toxic therapies, the patient dies of the disease or of complications of therapy. As our understanding about the role of tumor microenvironment in tumor progression and drug resistance improves, we are realizing that the paradigm of killing all cancer cells may be flawed.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Year:  2016        PMID: 26912901     DOI: 10.1126/scitranslmed.aaf3802

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  12 in total

1.  Anticancer Effects of Targeting Hsp70 in Tumor Stromal Cells.

Authors:  Vladimir L Gabai; Julia A Yaglom; Yongmei Wang; Le Meng; Hao Shao; Geunwon Kim; Teresa Colvin; Jason Gestwicki; Michael Y Sherman
Journal:  Cancer Res       Date:  2016-08-08       Impact factor: 12.701

2.  Modelling bistable tumour population dynamics to design effective treatment strategies.

Authors:  Andrei R Akhmetzhanov; Jong Wook Kim; Ryan Sullivan; Robert A Beckman; Pablo Tamayo; Chen-Hsiang Yeang
Journal:  J Theor Biol       Date:  2019-05-09       Impact factor: 2.405

3.  Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion.

Authors:  Kerstin Cornils; Lars Thielecke; Doreen Winkelmann; Tim Aranyossy; Mathias Lesche; Andreas Dahl; Ingo Roeder; Boris Fehse; Ingmar Glauche
Journal:  Mol Cancer       Date:  2017-07-14       Impact factor: 27.401

4.  Personalized anticancer therapy selection using molecular landscape topology and thermodynamics.

Authors:  Edward A Rietman; Jacob G Scott; Jack A Tuszynski; Giannoula Lakka Klement
Journal:  Oncotarget       Date:  2017-03-21

Review 5.  Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development.

Authors:  Melvin Kantono; Beichu Guo
Journal:  Front Immunol       Date:  2017-09-12       Impact factor: 7.561

Review 6.  Pyroptosis: mechanisms and diseases.

Authors:  Pian Yu; Xu Zhang; Nian Liu; Ling Tang; Cong Peng; Xiang Chen
Journal:  Signal Transduct Target Ther       Date:  2021-03-29

Review 7.  Future paradigms for precision oncology.

Authors:  Giannoula Lakka Klement; Knarik Arkun; Dalibor Valik; Tina Roffidal; Ali Hashemi; Christos Klement; Paolo Carmassi; Edward Rietman; Ondrej Slaby; Pavel Mazanek; Peter Mudry; Gabor Kovacs; Csongor Kiss; Koen Norga; Dobrin Konstantinov; Nicolas André; Irene Slavc; Henk van Den Berg; Alexandra Kolenova; Leos Kren; Jiri Tuma; Jarmila Skotakova; Jaroslav Sterba
Journal:  Oncotarget       Date:  2016-07-19

Review 8.  A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.

Authors:  Irina Kareva
Journal:  Int J Mol Sci       Date:  2017-10-13       Impact factor: 5.923

9.  Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside.

Authors:  Kristyna Polaskova; Tomas Merta; Alexandra Martincekova; Danica Zapletalova; Michal Kyr; Pavel Mazanek; Zdenka Krenova; Peter Mudry; Marta Jezova; Jiri Tuma; Jarmila Skotakova; Ivana Cervinkova; Dalibor Valik; Lenka Zdrazilova-Dubska; Hana Noskova; Karol Pal; Ondrej Slaby; Pavel Fabian; Sarka Kozakova; Jakub Neradil; Renata Veselska; Veronika Kanderova; Ondrej Hrusak; Tomas Freiberger; Giannoula Lakka Klement; Jaroslav Sterba
Journal:  Front Oncol       Date:  2020-02-07       Impact factor: 6.244

10.  Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.

Authors:  Alexander Zheleznyak; Matthew Mixdorf; Lynne Marsala; Julie Prior; Xiaoxia Yang; Grace Cui; Baogang Xu; Steven Fletcher; Francesca Fontana; Gregory Lanza; Samuel Achilefu
Journal:  Theranostics       Date:  2021-06-22       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.